[go: up one dir, main page]

MX353409B - Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular. - Google Patents

Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular.

Info

Publication number
MX353409B
MX353409B MX2015014216A MX2015014216A MX353409B MX 353409 B MX353409 B MX 353409B MX 2015014216 A MX2015014216 A MX 2015014216A MX 2015014216 A MX2015014216 A MX 2015014216A MX 353409 B MX353409 B MX 353409B
Authority
MX
Mexico
Prior art keywords
cell culture
molecular weight
high molecular
weight vwf
producing recombinant
Prior art date
Application number
MX2015014216A
Other languages
English (en)
Inventor
Grillberger Leopold
Reiter Manfred
Mundt Wolfgang
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX353409(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX353409B publication Critical patent/MX353409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un sobrenadante de cultivo de células que comprende el Factor Von Willebrand recombinante (rVWF), caracterizado porque al menos 20% del rVWF está presente en un multímero del VWF de alto peso molecular de más de 10 dímeros, en donde el sobrenadante de cultivo de células ha sido complementado para proporcionar una concentración final de cobre de al menos 2.4µg/L, y en donde el contenido de NH4+ del sobrenadante de cultivo de células se mantiene en una concentración por debajo de 4 mM o por debajo de 10 mM.
MX2015014216A 2010-07-08 2011-07-08 Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular. MX353409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08
PCT/US2011/043455 WO2012006591A1 (en) 2010-07-08 2011-07-08 METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE

Publications (1)

Publication Number Publication Date
MX353409B true MX353409B (es) 2018-01-11

Family

ID=44514323

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013000166A MX2013000166A (es) 2010-07-08 2011-07-08 Metodo para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular.
MX2013000165A MX339632B (es) 2010-07-08 2011-07-08 Metodo para producir adamts13 recombinante en cultivo celular.
MX2015014216A MX353409B (es) 2010-07-08 2011-07-08 Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2013000166A MX2013000166A (es) 2010-07-08 2011-07-08 Metodo para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular.
MX2013000165A MX339632B (es) 2010-07-08 2011-07-08 Metodo para producir adamts13 recombinante en cultivo celular.

Country Status (25)

Country Link
US (8) US8852888B2 (es)
EP (6) EP3064508B2 (es)
JP (3) JP5953502B2 (es)
KR (4) KR102027991B1 (es)
CN (4) CN103097409A (es)
AU (6) AU2011274470B2 (es)
BR (2) BR112013000515B1 (es)
CA (2) CA2804275A1 (es)
CO (2) CO6690745A2 (es)
DK (3) DK3064508T4 (es)
EA (5) EA035066B1 (es)
ES (4) ES2761692T5 (es)
FI (1) FI3064508T4 (es)
HR (3) HRP20192089T4 (es)
HU (3) HUE11738351T2 (es)
IL (5) IL286298B (es)
MX (3) MX2013000166A (es)
NZ (2) NZ605404A (es)
PL (4) PL3392271T3 (es)
PT (3) PT2590998T (es)
SG (3) SG10201809632XA (es)
SI (3) SI2591094T1 (es)
TR (1) TR201815211T4 (es)
TW (4) TWI617575B (es)
WO (2) WO2012006594A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670103B1 (ko) 2008-12-05 2016-10-27 박스알타 인코퍼레이티드 폰빌레브란트 인자의 ａｄａｍｔｓ１３－매개 생체내 절단을 측정하는 방법 및 그의 사용
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
HUE11738351T2 (hu) 2010-07-08 2019-03-28 Baxalta GmbH Eljárás rekombináns ADAMTS13 elõállítására sejttenyészetben
DK2717905T3 (en) * 2011-06-10 2018-07-02 Baxalta GmbH TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
CN106414719B (zh) * 2014-06-13 2020-02-14 杰特有限公司 生物反应器中重组von Willebrand因子的改进生产
MA41685A (fr) * 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
WO2016126339A1 (en) * 2015-02-05 2016-08-11 R.P. Scherer Technologies, Llc Activated formylglycine-generating enzymes and methods of producing and using the same
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
EP3493830A1 (en) 2016-08-04 2019-06-12 Baxalta Incorporated Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
EP3648788B1 (en) 2017-07-07 2024-05-22 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
WO2019010496A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION
EA202092223A1 (ru) 2018-03-21 2021-02-10 Баксалта Инкорпорейтед Разделение vwf и пропептида vwf хроматографическими методами
CA3128498A1 (en) 2019-02-01 2020-08-06 Bjorn Mellgard Methods of prophylactic treatment using recombinant vwf (rvwf)
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
US20220401524A1 (en) 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
CA3169996A1 (en) 2020-02-04 2021-08-12 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
EP4153215A1 (en) 2020-05-22 2023-03-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) † 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
AU591671B2 (en) 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0791055B1 (en) 1994-11-10 2012-01-25 Baxter Healthcare S.A. Method for producing biologicals in protein-free culture
JP3649249B2 (ja) 1995-02-23 2005-05-18 クエスト・インターナショナル・サービシーズ・ビー・ブイ 組織および細胞培養用ペプチド
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
EP1983044B1 (en) 1996-10-10 2016-08-10 Life Technologies Corporation Animal cell culture media comprising plant-derived nutrients
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
AU2002342922A1 (en) * 2001-11-28 2003-06-10 Sandoz Ag Cell culture process
EP1468099A2 (en) * 2002-01-17 2004-10-20 Lonza Biologics plc Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101052708B (zh) * 2004-11-02 2012-08-29 阿雷斯贸易股份有限公司 哺乳动物细胞的无血清细胞培养基
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
CN102643777A (zh) * 2006-01-04 2012-08-22 巴克斯特国际公司 无寡肽的细胞培养基
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
EP2527425A1 (en) * 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
CA2671676C (en) * 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
MX2009009240A (es) * 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
ES2649094T3 (es) * 2007-12-27 2018-01-10 Baxalta GmbH Procedimientos de cultivo celular
CN101910401A (zh) 2007-12-31 2010-12-08 巴克斯特国际公司 基本上无动物蛋白的重组体弗林蛋白酶及其生产方法
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
WO2009116044A2 (en) 2008-03-19 2009-09-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for treating bacterial infections
KR101286895B1 (ko) 2008-04-17 2013-07-16 와이어쓰 엘엘씨 골 형태발생 단백질의 개선된 생산 방법
US8486699B2 (en) * 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
MX2012001261A (es) * 2009-07-31 2012-05-22 Baxter Healthcare Sa Medio de cultivo de celula para la expresion de proteina adamts.
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
HUE11738351T2 (hu) * 2010-07-08 2019-03-28 Baxalta GmbH Eljárás rekombináns ADAMTS13 elõállítására sejttenyészetben
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
AU2015207811A1 (en) 2015-08-20
TWI646972B (zh) 2019-01-11
EA202090220A3 (ru) 2020-08-31
EP2591094A1 (en) 2013-05-15
CN107286235A (zh) 2017-10-24
WO2012006594A1 (en) 2012-01-12
US9458222B2 (en) 2016-10-04
TW201204744A (en) 2012-02-01
JP5953502B2 (ja) 2016-07-20
KR102007773B1 (ko) 2019-08-06
EA029503B1 (ru) 2018-04-30
JP6138683B2 (ja) 2017-05-31
US20190085052A1 (en) 2019-03-21
IL223929A (en) 2017-11-30
DK3064508T3 (da) 2019-11-25
AU2020203565B2 (en) 2021-09-30
BR112013000515A2 (pt) 2016-05-17
FI3064508T4 (fi) 2023-04-25
US20150056657A1 (en) 2015-02-26
US8852888B2 (en) 2014-10-07
KR102027991B1 (ko) 2019-10-02
US20120035110A1 (en) 2012-02-09
PT3064508T (pt) 2019-12-05
ES2761692T3 (es) 2020-05-20
PL3392271T3 (pl) 2021-11-15
HRP20192089T4 (hr) 2023-04-28
EP3909977A1 (en) 2021-11-17
EA035066B1 (ru) 2020-04-23
NZ605403A (en) 2014-10-31
AU2020203565A1 (en) 2020-06-18
EA202090067A3 (ru) 2020-07-31
PT2590998T (pt) 2018-02-13
IL255327A0 (en) 2017-12-31
JP6284919B2 (ja) 2018-02-28
CO6680636A2 (es) 2013-05-31
ES2664392T3 (es) 2018-04-19
BR112013000515B1 (pt) 2021-11-03
KR101894604B1 (ko) 2018-09-03
US20150018525A1 (en) 2015-01-15
EP3392271B8 (en) 2021-06-16
EP2590998B1 (en) 2017-11-15
US20180044405A1 (en) 2018-02-15
EA202090067A2 (ru) 2020-04-30
DK2590998T3 (en) 2018-02-12
WO2012006591A1 (en) 2012-01-12
IL286298B (en) 2022-08-01
DK3064508T4 (da) 2023-04-11
HUE046443T2 (hu) 2020-03-30
EP3064508B1 (en) 2019-08-28
EP3626736A1 (en) 2020-03-25
CO6690745A2 (es) 2013-06-17
KR20180130587A (ko) 2018-12-07
JP2013533748A (ja) 2013-08-29
SI2590998T1 (en) 2018-06-29
EP3392271B1 (en) 2021-05-05
MX2013000165A (es) 2013-06-05
KR20180099922A (ko) 2018-09-05
BR112013000512A2 (pt) 2016-05-17
PL3064508T3 (pl) 2020-02-28
EA201792340A3 (ru) 2018-07-31
SG186936A1 (en) 2013-02-28
KR20130091329A (ko) 2013-08-16
US9834591B2 (en) 2017-12-05
IL273304A (en) 2020-04-30
CN103097522A (zh) 2013-05-08
HRP20192089T1 (hr) 2020-03-20
EA201792340A2 (ru) 2018-02-28
NZ605404A (en) 2014-08-29
EA202090220A2 (ru) 2020-05-31
IL273304B (en) 2021-09-30
JP2017217004A (ja) 2017-12-14
CN103097409A (zh) 2013-05-08
AU2018200206B2 (en) 2020-05-28
TR201815211T4 (tr) 2018-11-21
AU2015207811B2 (en) 2017-10-19
AU2018200206A1 (en) 2018-04-05
HUE11738351T2 (hu) 2019-03-28
MX339632B (es) 2016-06-02
JP2013538046A (ja) 2013-10-10
PL2591094T3 (pl) 2019-02-28
US9409971B2 (en) 2016-08-09
EP3064508A1 (en) 2016-09-07
PT2591094T (pt) 2018-11-20
CN108060154A (zh) 2018-05-22
SG10201809632XA (en) 2018-12-28
PL3064508T5 (pl) 2024-04-08
ES2761692T5 (es) 2023-07-05
HUE038193T2 (hu) 2018-09-28
SI2591094T1 (sl) 2018-12-31
US20170008948A1 (en) 2017-01-12
TWI617575B (zh) 2018-03-11
TW201206953A (en) 2012-02-16
IL286298A (en) 2021-10-31
HRP20181657T1 (hr) 2019-03-08
SI3064508T1 (sl) 2019-12-31
TW201900207A (zh) 2019-01-01
US20120034674A1 (en) 2012-02-09
KR101924120B1 (ko) 2018-11-30
TWI670073B (zh) 2019-09-01
PL2590998T3 (pl) 2018-05-30
SI3064508T2 (sl) 2023-05-31
CA2804275A1 (en) 2012-01-12
EA201390080A1 (ru) 2013-06-28
AU2022200035A1 (en) 2022-01-20
MX2013000166A (es) 2013-06-05
ES2875772T3 (es) 2021-11-11
DK2591094T3 (en) 2018-11-26
AU2011274467A1 (en) 2013-01-24
JP2016025873A (ja) 2016-02-12
EA035147B1 (ru) 2020-05-06
EP3392271A1 (en) 2018-10-24
US20210115110A1 (en) 2021-04-22
EP2591094B1 (en) 2018-09-05
EP2590998A1 (en) 2013-05-15
TWI609890B (zh) 2018-01-01
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
HRP20180136T1 (hr) 2018-04-06
EA201390082A1 (ru) 2013-06-28
US10822394B2 (en) 2020-11-03
AU2011274467B2 (en) 2015-01-15
AU2011274470A1 (en) 2013-01-24
US10100099B2 (en) 2018-10-16
EP3064508B2 (en) 2023-03-15
TW201637665A (zh) 2016-11-01
AU2011274470B2 (en) 2015-08-13
IL223930A (en) 2017-01-31
CA2805557A1 (en) 2012-01-12
ES2694518T3 (es) 2018-12-21
IL255327B (en) 2020-04-30
US11780904B2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
MX353409B (es) Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
EA201270224A1 (ru) Среда для культивирования клеток для экспрессии белков adamts
IN2015DN01365A (es)
GEP20217251B (en) Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
PH12014501063A1 (en) A method for producing a target substance by fermentation
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
MX365435B (es) Metodos de modificacion de celulas huesped.
WO2010096588A3 (en) Cell culture media containing combinations of proteins
IN2014DN10996A (es)
WO2013016724A3 (en) Decarboxylase proteins with high keto-isovalerate decarboxylase activity
WO2011091350A3 (en) Methods & compositions for improving protein production
MX2020004988A (es) Microorganismo capaz de producir l-aminoacido, y un metodo para producir l-aminoacido usando el mismo.
IN2015MN00436A (es)
EP2576804A4 (en) PENTOSE FERMENTATION BY RECOMBINANT MICROORGANISM
WO2012177983A3 (en) Microorganisms for producing ethylene glycol and methods related thereto
PH12013501592A1 (en) Novel use of a dense and erect panicle 1 gene in improving nitrogen utilization efficiency
EP3536799A3 (en) Engineered enzyme having acetoacetyl-coa hydrolase activity, microorganisms comprising same, and methods of using same
SG10201803572UA (en) Control of carbon dioxide levels and ph in small volume reactors
MX350005B (es) Microorganismos fermentadores de pentosa.
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
MX2017014663A (es) Metodo para producir una proteina recombinante.
NZ705488A (en) Picornavirus-like particle production in plants
Spasova FOREIGN SPECIALISTS ADAPTATION TO THE SOVIET LIFE REALITY (BASED ON MAGNITOSTROY EXPERIENCE)